A new chance to beat diabetic kidney disease: Innate immunity and MCP-1: A matter of good and bad macrophages?

Nephrology Dialysis Transplantation

Volumn 30, Issue 4, 2015, Pages 525-527

  Gnudi, Luigi ^a  

^a Department of Pharmacy   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1;

ARTICLE; CELL INFILTRATION; CHRONIC DISEASE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; HUMAN; INNATE IMMUNITY; MACROPHAGE; MACROPHAGE ACTIVATION; NONHUMAN; PATHOPHYSIOLOGY; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINALYSIS;

EID: 84926634023     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv053     Document Type: Article

References (17)

1. Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008; 294: F697-F701
2. Mauer M, Zinman B, Gardiner R et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361: 40-51
3. Wada T, Furuichi K, Sakai N et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000; 58: 1492-1499
4. Mezzano S, Aros C, Droguett A et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004; 19: 2505-2512
5. Amann B, Tinzmann R, Angelkort B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 2003; 26: 2421-2425
6. Yang B, Houlberg K, Millward A et al. Polymorphisms of chemokine and chemokine receptor genes in Type 1 diabetes mellitus and its complications. Cytokine 2004; 26: 114-121
7. Sullivan T, Miao Z, Dairaghi DJ et al. CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. Am J Physiol Renal Physiol 2013; 305: F1288-F1297
8. Sayyed SG, Ryu M, Kulkarni OP et al. An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney Int 2011; 80: 68-78
9. Maasch C, Buchner K, Eulberg D et al. Physicochemical stability of NOXE36, a 40mer L-RNA (Spiegelmer) for therapeutic applications. Nucleic Acids Symp Ser (Oxf) 2008; 52: 61-62
10. Mills CD. M1 and M2 Macrophages: Oracles of Health and Disease. Crit Rev Immunol 2012; 32: 463-488
11. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 2014; 6: 13
12. Martinez FO, Sica A, Mantovani A et al. Macrophage activation and polarization. Front Biosci 2008; 13: 453-461
13. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012; 122: 787-795
14. You H, Gao T, Cooper TK et al. Macrophages directly mediate diabetic renal injury. Am J Physiol Renal Physiol 2013; 305: F1719-F1727
15. Lee S, Huen S, Nishio H et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol 2011; 22: 317-326
16. Cucak H, Nielsen Fink L, Hojgaard Pedersen M et al. Enalapril treatment increases T cell number and promotes polarization towards M1-likemacrophages locally in diabetic nephropathy. Int Immunopharmacol 2015; 25: 30-42
17. Roca H, Varsos ZS, Sud S et al. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 2009; 284: 34342-34354